COLL Collegium Pharmaceutical, Inc.
Collegium Pharmaceutical, Inc. (COLL) is expected to report earnings on February 4, 2027, before the market open. The consensus earnings estimate is $1.61 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +0.7% since its last earnings release on November 5, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Collegium Pharmaceutical, Inc.
Collegium is a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions.
Sector
Healthcare
Industry
Drug Manufacturers/Other
Held By 3 ETFs, by dollar flow
Charts powered in part by Lightweight Charts™ by TradingView.